Novel mucosal DNA-MVA HIVVaccination in which DNA-IL-12 plus cholera toxin B subunit (CTB) cooperates to enhance cellular systemic and mucosal genital tract immunity

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Maeto, Cynthia ^a   Rodríguez, Ana María ^a   Holgado, María Pía ^a   Falivene, Juliana ^a   Gherardi, María Magdalena ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; CHOLERA TOXIN B SUBUNIT; DNA; DNA VACCINE; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 2; TUMOR NECROSIS FACTOR ALPHA; VIRUS ENVELOPE PROTEIN; CHOLERA TOXIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MVA VACCINE; VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; DNA IMMUNIZATION; DRUG EFFICACY; FEMALE; FIBROBLAST; GENITAL SYSTEM; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VIVO STUDY; LYMPH NODE; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; SPLEEN; T LYMPHOCYTE SUBPOPULATION; ANIMAL; DRUG EFFECTS; GENITAL TRACT INFECTION; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; MUCOSA; PATHOGENICITY; PATHOLOGY; VIROLOGY;

AIDS VACCINES; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CHOLERA TOXIN; HIV INFECTIONS; HIV-1; HUMANS; IMMUNITY, MUCOSAL; INTERLEUKIN-12; MICE; MUCOUS MEMBRANE; REPRODUCTIVE TRACT INFECTIONS; VACCINES, DNA; VIRAL VACCINES;

EID: 84928140506     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0107524     Document Type: Article

References (56)

1. Haase AT (2005) Perils at mucosal front lines for HIV and SIV and their hosts. Nat Rev Immunol 5: 783-792.
2. Haase AT (2010) Targeting early infection to prevent HIV-1 mucosal transmission. Nature 464: 217-223.
3. Cripps AW, Kyd JM, Foxwell AR (2001) Vaccines and mucosal immunisation. Vaccine 19: 2513-2515.
4. Ogra PL, Faden H, Welliver RC (2001) Vaccination strategies for mucosal immune responses. Clin Microbiol Rev 14: 430-445.
5. Gherardi MM, Perez-Jimenez E, Najera JL, Esteban M (2004) Induction of HIV immunity in the genital tract after intranasal delivery of a MVA vector: enhanced immunogenicity after DNA prime-modified vaccinia virus Ankara boost immunization schedule. J Immunol 172: 6209-6220.
6. Bertley FM, Kozlowski PA, Wang SW, Chappelle J, Patel J, et al. (2004) Control of simian/human immunodeficiency virus viremia and disease progression after IL-2-augmented DNA-modified vaccinia virus Ankara nasal vaccination in nonhuman primates. J Immunol 172: 3745-3757.
7. Manrique M, Kozlowski PA, Wang SW, Wilson RL, Micewicz E, et al. (2009) Nasal DNA-MVA SIV vaccination provides more significant protection from progression to AIDS than a similar intramuscular vaccination. Mucosal Immunol 2: 536-550.
8. Lycke N (2010) Recent progress in mucosal vaccine development: potential and limitations. Nat Rev Immunol 12: 592-605.
9. Manrique M, Kozlowski PA, Cobo-Molinos A, Wang SW, Wilson RL, et al. (2011) Long-term control of simian immunodeficiency virus mac251 viremia to undetectable levels in half of infected female rhesus macaques nasally vaccinated with simian immunodeficiency virus DNA/recombinant modified vaccinia virus Ankara. J Immunol 186: 3581-3593.
10. Gherardi MM, Esteban M (2005) Recombinant poxviruses as mucosal vaccine vectors. J Gen Virol 86: 2925-2936.
11. Appay V, Douek DC, Price DA (2008) CD8+ T cell efficacy in vaccination and disease. Nat Med 14: 623-628.
12. Gherardi MM, Ramirez JC, Esteban M (2000) Interleukin-12 (IL-12) enhancement of the cellular immune response against human immunodeficiency virus type 1 env antigen in a DNA prime/vaccinia virus boost vaccine regimen is time and dose dependent: suppressive effects of IL-12 boost are mediated by nitric oxide. J Virol 74: 6278-6286.
13. Gherardi MM, Ramirez JC, Esteban M (2001) Towards a new generation of vaccines: the cytokine IL-12 as an adjuvant to enhance cellular immune responses to pathogens during prime-booster vaccination regimens. Histology and histopathology 16: 655-667.
14. Winstone N, Wilson AJ, Morrow G, Boggiano C, Chiuchiolo MJ, et al. (2011) Enhanced control of pathogenic Simian immunodeficiency virus SIVmac239 replication in macaques immunized with an interleukin-12 plasmid and a DNA prime-viral vector boost vaccine regimen. J Virol 85: 9578-9587.
15. Arulanandam BP, Metzger DW (1999) Modulation of mucosal and systemic immunity by intranasal interleukin 12 delivery. Vaccine 17: 252-260.
16. Wright AK, Briles DE, Metzger DW, Gordon SB (2008) Prospects for use of interleukin-12 as a mucosal adjuvant for vaccination of humans to protect against respiratory pneumococcal infection. Vaccine 26: 4893-4903.
17. Albu DI, Jones-Trower A, Woron AM, Stellrecht K, Broder CC, et al. (2003) Intranasal vaccination using interleukin-12 and cholera toxin subunit B as adjuvants to enhance mucosal and systemic immunity to human immunodeficiency virus type 1 glycoproteins. J Virol 77: 5589-5597.
18. Andre S, Seed B, Eberle J, Schraut W, Bultmann A, et al. (1998) Increased immune response elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usage. J Virol 72: 1497-1503.
19. Tapia E, Perez-Jimenez E, Lopez-Fuertes L, Gonzalo R, Gherardi MM, et al. (2003) The combination of DNA vectors expressing IL-12 + IL-18 elicits high protective immune response against cutaneous leishmaniasis after priming with DNA-p36/LACK and the cytokines, followed by a booster with a vaccinia virus recombinant expressing p36/LACK. Microbes Infect 5: 73-84.
20. Ramirez JC, Gherardi MM, Rodriguez D, Esteban M (2000) Attenuated modified vaccinia virus Ankara can be used as an immunizing agent under conditions of preexisting immunity to the vector. J Virol 74: 7651-7655.
21. Ramirez JC, Gherardi MM, Esteban M (2000) Biology of attenuated modified vaccinia virus Ankara recombinant vector in mice: virus fate and activation of Band T-cell immune responses in comparison with the Western Reserve strain and advantages as a vaccine. Journal of virology 74: 923-933.
22. Dallo S, Esteban M (1987) Isolation and characterization of attenuated mutants of vaccinia virus. Virology 159: 408-422.
23. Ferko B, Katinger D, Grassauer A, Egorov A, Romanova J, et al. (1998) Chimeric influenza virus replicating predominantly in the murine upper respiratory tract induces local immune responses against human immunodeficiency virus type 1 in the genital tract. J Infect Dis 178: 1359-1368.
24. Bergmann C, Stohlmann SA, McMillan M (1993) An endogenously synthesized decamer peptide efficiently primes cytotoxic T cells specific for the HIV-1 envelope glycoprotein. Eur J Immunol 23: 2777-2781.
25. Rodriguez AM, Turk G, Pascutti MF, Ferrer F, Najera JL, et al. (2009) Characterization of DNA and MVA vectors expressing Nef from HIV-1 CRF12-BF revealed high immune specificity with low cross-reactivity against subtype B. Virus Res 146: 1-12.
26. Almeida JR, Price DA, Papagno L, Arkoub ZA, Sauce D, et al. (2007) Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover. J Exp Med 204: 2473-2485.
27. Betts MR, Brenchley JM, Price DA, De Rosa SC, Douek DC, et al. (2003) Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods 281: 65-78.
28. Rodriguez AM, Pascutti MF, Maeto C, Falivene J, Holgado MP, et al. (2012) IL-12 and GM-CSF in DNA/MVA immunizations against HIV-1 CRF12-BF Nef induced T-cell responses with an enhanced magnitude, breadth and quality. PloS one 7: e37801.
29. Coles RM, Mueller SN, Heath WR, Carbone FR, Brooks AG (2002) Progression of armed CTL from draining lymph node to spleen shortly after localized infection with herpes simplex virus 1. J Immunol 168: 834-838.
30. Durward M, Harms J, Splitter G (2010) Antigen specific killing assay using CFSE labeled target cells. J Vis Exp.
31. Freel SA, Lamoreaux L, Chattopadhyay PK, Saunders K, Zarkowsky D, et al. (2010) Phenotypic and functional profile of HIV-inhibitory CD8 T cells elicited by natural infection and heterologous prime/boost vaccination. J Virol 84: 4998-5006.
32. Turk G, Ghiglione Y, Falivene J, Socias ME, Laufer N, et al. (2013) Early Gag immunodominance of the HIV-specific T-cell response during acute/early infection is associated with higher CD8+ T-cell antiviral activity and correlates with preservation of the CD4+ T-cell compartment. J Virol 87: 7445-7462.
33. Vingert B, Perez-Patrigeon S, Jeannin P, Lambotte O, Boufassa F, et al. (2010) HIV controller CD4+ T cells respond to minimal amounts of Gag antigen due to high TCR avidity. PLoS Pathog 6: e1000780.
34. Berger CT, Frahm N, Price DA, Mothe B, Ghebremichael M, et al. (2011) High-functional-avidity cytotoxic T lymphocyte responses to HLA-B-restricted Gag-derived epitopes associated with relative HIV control. J Virol 85: 9334-9345.
35. Lopalco L, Bomsel M (2011) Protecting the initial site of viral entry: an alternative HIV vaccine target. Expert Rev Vaccines 10: 1253-1256.
36. Holmgren J, Czerkinsky C (2005) Mucosal immunity and vaccines. Nat Med 11: S45-53.
37. Luci C, Hervouet C, Rousseau D, Holmgren J, Czerkinsky C, et al. (2006) Dendritic cell-mediated induction of mucosal cytotoxic responses following intravaginal immunization with the nontoxic B subunit of cholera toxin. J Immunol 176: 2749-2757.
38. Hervouet C, Luci C, Cuburu N, Cremel M, Bekri S, et al. (2010) Sublingual immunization with an HIV subunit vaccine induces antibodies and cytotoxic T cells in the mouse female genital tract. Vaccine 28: 5582-5590.
39. Matoba N, Geyer BC, Kilbourne J, Alfsen A, Bomsel M, et al. (2006) Humoral immune responses by prime-boost heterologous route immunizations with CTB-MPR(649-684), a mucosal subunit HIV/AIDS vaccine candidate. Vaccine 24: 5047-5055.
40. Staats HF, Bradney CP, Gwinn WM, Jackson SS, Sempowski GD, et al. (2001) Cytokine requirements for induction of systemic and mucosal CTL after nasal immunization. J Immunol 167: 5386-5394.
41. Belyakov IM, Ahlers JD, Clements JD, Strober W, Berzofsky JA (2000) Interplay of cytokines and adjuvants in the regulation of mucosal and systemic HIV-specific CTL. J Immunol 165: 6454-6462.
42. Winstone N, Wilson AJ, Morrow G, Boggiano C, Chiuchiolo MJ, et al. (2011) Enhanced control of pathogenic Simian immunodeficiency virus SIVmac239 replication in macaques immunized with an interleukin-12 plasmid and a DNA prime-viral vector boost vaccine regimen. Journal of virology 85: 9578-9587.
43. Genesca M, McChesney MB, Miller CJ (2009) Antiviral CD8+ T cells in the genital tract control viral replication and delay progression to AIDS after vaginal SIV challenge in rhesus macaques immunized with virulence attenuated SHIV 89.6. J Intern Med 265: 67-77.
44. Ranasinghe C, Trivedi S, Stambas J, Jackson RJ (2013) Unique IL-13Ralpha2-based HIV-1 vaccine strategy to enhance mucosal immunity, CD8(+) T-cell avidity and protective immunity. Mucosal Immunol 6: 1068-1080.
45. Ranasinghe C, Turner SJ, McArthur C, Sutherland DB, Kim JH, et al. (2007) Mucosal HIV-1 pox virus prime-boost immunization induces high-avidity CD8+ T cells with regime-dependent cytokine/granzyme B profiles. J Immunol 178: 2370-2379.
46. Markiewicz MA, Wise EL, Buchwald ZS, Cheney EE, Hansen TH, et al. (2009) IL-12 enhances CTL synapse formation and induces self-reactivity. J Immunol 182: 1351-1361.
47. DeBenedette MA, Calderhead DM, Ketteringham H, Gamble AH, Horvati-novich JM, et al. (2008) Priming of a novel subset of CD28+ rapidly expanding high-avidity effector memory CTL by post maturation electroporation-CD40L dendritic cells is IL-12 dependent. J Immunol 181: 5296-5305.
48. Li Z, Zhang M, Zhou C, Zhao X, Iijima N, et al. (2008) Novel vaccination protocol with two live mucosal vectors elicits strong cell-mediated immunity in the vagina and protects against vaginal virus challenge. J Immunol 180: 2504-2513.
49. Wick WD, Yang OO (2012) Biologically-directed modeling reflects cytolytic clearance of SIV-infected cells in vivo in macaques. PloS one 7: e44778.
50. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A (1999) Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401: 708-712.
51. Zhang Y, Joe G, Hexner E, Zhu J, Emerson SG (2005) Host-reactive CD8+ memory stem cells in graft-versus-host disease. Nat Med 11: 1299-1305.
52. Gattinoni L, Zhong XS, Palmer DC, Ji Y, Hinrichs CS, et al. (2009) Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells. Nat Med 15: 808-813.
53. Gattinoni L, Lugli E, Ji Y, Pos Z, Paulos CM, et al. (2011) A human memory T cell subset with stem cell-like properties. Nat Med 17: 1290-1297.
54. Li G, Yang Q, Zhu Y, Wang HR, Chen X, et al. (2013) T-Bet and Eomes Regulate the Balance between the Effector/Central Memory T Cells versus Memory Stem Like T Cells. PloS one 8: e67401.
55. Precopio ML, Betts MR, Parrino J, Price DA, Gostick E, et al. (2007) Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(+) T cell responses. J Exp Med 204: 1405-1416.
56. Kipnis A, Irwin S, Izzo AA, Basaraba RJ, Orme IM (2005) Memory T lymphocytes generated by Mycobacterium bovis BCG vaccination reside within a CD4 CD44lo CD62 ligand(hi) population. Infect Immun 73: 7759-7764.